Steven Riesinger
About Steven Riesinger
Steven Riesinger Co-Founder
Steven Riesinger holds the title of Co-Founder, a role that indicates leadership and entrepreneurial responsibility within an organization. As Co-Founder, his duties likely encompass strategic decision-making, oversight of operations, and significant contributions to the company's vision and direction. His position involves collaboration with other key stakeholders to drive the company’s goals forward.
Research on GPR158 Overexpression
Steven Riesinger co-authored a paper titled 'Regulatory Effects of GPR158 Overexpression in Trabecular Meshwork Cells of the Eye’s Aqueous Outflow Pathways,' which was published in the journal Stresses. This research explores the effects of overexpression of the GPR158 protein in trabecular meshwork cells, with implications for understanding and potentially treating eye conditions related to aqueous outflow pathways.
Contribution to Anticancer Prodrug Research
Steven Riesinger contributed to research on 'WR1065 conjugated to thiol-PEG polymers as novel anticancer prodrugs,' published in Frontiers in Oncology. This study investigated the potential of WR1065, a compound conjugated to thiol-PEG polymers, to serve as a novel prodrug in anticancer treatments. The research aimed to enhance the efficacy and specificity of cancer therapeutics.
Scientific Collaboration Integrating Chemistry and Biology
Steven Riesinger is involved in a scientific collaboration focused on integrating chemistry and biology to streamline discovery and development programs. This collaboration seeks to leverage interdisciplinary approaches to enhance the efficiency and effectiveness of research and development processes, particularly in the fields of chemistry and biology.